Beam Therapeutics Inc
XNAS:BEAM
| Market Cap (Intraday) | 2.74B |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $26.43 |
| 50-Day MA | $25.26 |
| 200-Day MA | $21.02 |
Beam Therapeutics Inc Stock, XNAS:BEAM
238 Main Street, 9th floor, Cambridge, Massachusetts 02142-1016
United States of America
Phone: +1.857.327.8775
Number of Employees: 483
Description
Beam Therapeutics, Inc. is a biotechnology company, which engages in the establishment of integrated platform for precision genetic medicines. Its pipeline includes BEAM-101, BEAM-302, Engineered Stem Cell Antibody Paired Evasion (ESCAPE), BEAM-301, and BEAM-201. The company was founded by David R. Liu, Feng Zhang, Alexis Komor, Nicole Gaudelli, and J. Keith Joung on January 25, 2017 and is headquartered in Cambridge, MA.


